CEO and R&D Director

Tim Sparey & Andrew Ratcliffe

Bailey Fisher Executive Search is pleased to have worked with early stage oncology therapeutics company, Novintum Bioscience, to appoint a CEO and R&D Director.

Bailey Fisher Executive Search was engaged by Rising Tide, a US/Swiss fund, to manage the search for a CEO for Novintum Bioscience, one of their portfolio companies.  The search resulted in the appointment of Tim Sparey, an experienced pharmaceutical professional with a background in blue chip, large and specialty pharma, as well as earlier stage biotech companies.

Following Tim’s appointment as CEO, Bailey Fisher was re-engaged by Novintum Bioscience to lead the search for an experienced “drug hunter” as R&D Director, to work alongside the CSO as a senior executive leader in the organisation.  The search resulted in the appointment of Andrew Ratcliffe, an internationally experienced and highly motivated R&D Director.

 

 

 

Ken Cunningham

Bailey Fisher Executive Search is pleased to have worked with Medherant on the search for a Chair of the Board.

Medherant is a specialty pharma company creating a sustainable, next-generation transdermal drug delivery patch that creates value for patients, partners and investors. The company is a spin-out from the University of Warwick.

Bailey Fisher Executive Search was engaged by the investor to manage the search for a Chair to lead the Board and work alongside the CEO during a critical period in the company’s development.

The search resulted in the appointment of Ken Cunningham as Chair of the Board. Ken has over 25 years’ experience in the pharmaceutical industry, including leadership roles with SkyePharma plc, initially as COO and subsequently as CEO. He is currently Chair at Abzena and NED at Xention Pharma.

The search was led by Paul Bailey,  Founding Partner at Bailey Fisher Executive Search.